[go: up one dir, main page]

MA33746B1 - Combinaison - Google Patents

Combinaison

Info

Publication number
MA33746B1
MA33746B1 MA34863A MA34863A MA33746B1 MA 33746 B1 MA33746 B1 MA 33746B1 MA 34863 A MA34863 A MA 34863A MA 34863 A MA34863 A MA 34863A MA 33746 B1 MA33746 B1 MA 33746B1
Authority
MA
Morocco
Prior art keywords
pharmaceutically acceptable
acceptable salt
raf
mek
inhibitor
Prior art date
Application number
MA34863A
Other languages
Arabic (ar)
English (en)
Inventor
Melissa Dumble
Rakesh Kumar
Sylvie Laquerre
Peter Lebowitz
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43876568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33746(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MA33746B1 publication Critical patent/MA33746B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

L'INVENTION CONCERNE UNE NOUVELLE COMBINAISON COMPRENANT L'INHIBITEUR DE MEK N-{3-[3-CYCLOPROPYL-5- (2-FLUORO-4-IODO-PHÉNYLAMINO)6,8-DIMÉTHYL; -2,4,7-TRIOXO-3,4,6,7-TÉTRAHYDRO-2H-PYRIDO [4,3-D]PYRIMIDIN-1-YL]PHÉNYL}ACÉTAMIDE OU UN SEL OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI AVEC UN INHIBITEUR DE B-RAF, EN PARTICULIER LE N-{3- [5-(2-AMINO-4-PYRIMIDINYL)-2-(1,1-DIMÉTHYLÉTHYL)-1, 3-THIAZOL-4-YL]-2-FLUOROPHÉNYL}-2,6-DIFLUOROBENZÈNESULFONAMIDE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, DES COMPOSITIONS PHARMACEUTIQUES LES COMPRENANT ET DES PROCÉDÉS D'UTILISATION DE TELLES COMBINAISONS ET COMPOSITIONS DANS LE TRAITEMENT D'ÉTATS PATHOLOGIQUES DANS LESQUELS L'INHIBITION DE MEK ET/OU B-RAF EST BÉNÉFIQUE, PAR EXEMPLE LE CANCER.
MA34863A 2009-10-16 2012-05-11 Combinaison MA33746B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25221309P 2009-10-16 2009-10-16
PCT/US2010/052808 WO2011047238A1 (fr) 2009-10-16 2010-10-15 Combinaison

Publications (1)

Publication Number Publication Date
MA33746B1 true MA33746B1 (fr) 2012-11-01

Family

ID=43876568

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34863A MA33746B1 (fr) 2009-10-16 2012-05-11 Combinaison

Country Status (35)

Country Link
US (3) US8703781B2 (fr)
EP (4) EP2488033B1 (fr)
JP (1) JP5718929B2 (fr)
KR (1) KR101729116B1 (fr)
CN (1) CN102655753B (fr)
AU (1) AU2010306653B2 (fr)
BR (1) BR112012008854B8 (fr)
CA (1) CA2775803C (fr)
CL (1) CL2012000964A1 (fr)
CO (1) CO6531498A2 (fr)
CR (1) CR20120155A (fr)
CY (1) CY1122013T1 (fr)
DK (3) DK2488033T3 (fr)
DO (1) DOP2012000091A (fr)
EA (1) EA020589B1 (fr)
ES (3) ES2930157T3 (fr)
FI (1) FI4159217T3 (fr)
HR (2) HRP20191617T1 (fr)
HU (3) HUE046139T2 (fr)
IL (1) IL219073A (fr)
LT (3) LT4159217T (fr)
MA (1) MA33746B1 (fr)
ME (1) ME03497B (fr)
MX (1) MX2012004413A (fr)
MY (1) MY174759A (fr)
NZ (1) NZ598913A (fr)
PE (1) PE20121093A1 (fr)
PH (1) PH12012500742A1 (fr)
PL (3) PL3560498T3 (fr)
PT (3) PT4159217T (fr)
RS (3) RS65800B1 (fr)
SI (2) SI4159217T1 (fr)
UA (1) UA105064C2 (fr)
WO (1) WO2011047238A1 (fr)
ZA (1) ZA201202612B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8592465B2 (en) 2008-06-16 2013-11-26 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
JP5985401B2 (ja) 2010-03-09 2016-09-06 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 第一の癌療法に対する耐性を現に有するか、または、そのような耐性を生じる患者において癌を診断および治療する方法
JP2014505658A (ja) * 2010-11-05 2014-03-06 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド 癌を治療する方法
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
EP2791169B1 (fr) 2011-12-16 2017-07-19 Synthon Biopharmaceuticals B.V. Composés et méthodes de traitement de maladies inflammatoires
RU2014122867A (ru) * 2011-12-22 2016-02-20 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Способ лечения рака иммунотерапевтическим средством, специфичным в отношении MAGEA3, совместно с ингибитором BRAF и/или ингибитором MEK
JP2015511632A (ja) * 2012-03-30 2015-04-20 武田薬品工業株式会社 メラノーマの治療におけるｒａｆ阻害剤およびｍｅｋ阻害剤の投与
WO2014039375A1 (fr) * 2012-09-04 2014-03-13 Glaxosmithkline Llc Procédé de traitement du cancer par adjuvant
CN104812391A (zh) * 2012-10-25 2015-07-29 葛兰素史克公司 组合
EA028246B1 (ru) * 2012-11-30 2017-10-31 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Фармацевтическая композиция
CN103965170A (zh) * 2013-01-24 2014-08-06 通化济达医药有限公司 苯磺酰胺吡唑激酶抑制剂
US10022356B2 (en) * 2013-03-05 2018-07-17 University Of Tennessee Research Foundation Compounds for treatment of cancer
WO2014193898A1 (fr) * 2013-05-31 2014-12-04 Merck Sharp & Dohme Corp. Thérapies combinées contre le cancer
BR112015028326A8 (pt) * 2013-06-03 2018-01-23 Novartis Ag combinações de anticorpo anti-pd-l1, inibidor de mek e/ou inibidor de braf, seus kits e seus usos, e composição farmacêutica
CN104540822B (zh) * 2013-07-08 2016-08-31 杭州普晒医药科技有限公司 达拉菲尼甲磺酸盐的晶型及其制备方法
WO2015059677A1 (fr) * 2013-10-26 2015-04-30 Glaxosmithkline Intellectual Property (No.2) Limited Méthodes de traitement du cancer
CN103588767B (zh) * 2013-11-20 2016-01-20 苏州明锐医药科技有限公司 达拉菲尼的制备方法
CA2933311A1 (fr) * 2013-12-12 2015-06-18 Novartis Ag Combinaisons de trametinib, panitumumab et dabrafenib pour le traitement du cancer
SG10201804519RA (en) 2013-12-28 2018-07-30 Guardant Health Inc Methods and systems for detecting genetic variants
WO2015105822A1 (fr) * 2014-01-07 2015-07-16 Glaxosmithkline Llc Procédé de traitement du cancer
AU2015256208B2 (en) 2014-05-06 2020-01-02 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
KR101629184B1 (ko) 2014-12-10 2016-06-13 현대오트론 주식회사 Autosar 플랫폼에서의 eeprom 처리속도 향상을 위한 주기함수 호출 방법
WO2017033113A1 (fr) 2015-08-21 2017-03-02 Acerta Pharma B.V. Associations thérapeutiques d'un inhibiteur de mek et d'un inhibiteur de btk
CN110022878A (zh) * 2016-11-03 2019-07-16 密执安大学评议会 Egfr/pi3k的小分子双重抑制剂及其用途
WO2020079581A1 (fr) 2018-10-16 2020-04-23 Novartis Ag Charge mutationnelle tumorale seule ou en combinaison avec des marqueurs immunitaires comme biomarqueurs pour prédire une réponse à une thérapie ciblée
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
WO2021018032A1 (fr) * 2019-07-26 2021-02-04 Ascentage Pharma (Suzhou) Co., Ltd. Composition pharmaceutique d'inhibiteur de mdm2 et son utilisation pour prévenir et/ou traiter une maladie
CA3149796A1 (fr) 2019-08-02 2021-02-11 Onehealthcompany, Inc. Agents anticancereux pour le traitement des cancers canins
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021118924A2 (fr) 2019-12-12 2021-06-17 Ting Therapeutics Llc Compositions et méthodes de prévention et de traitement de la perte d'audition
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
US20230084515A1 (en) * 2020-02-19 2023-03-16 Vanderbilt University Therapeutic methods and compositions for treating cancer using braf and/or mek inhibitor combination therapy
US12014835B2 (en) 2020-02-19 2024-06-18 Vanderbilt University Methods for evaluating therapeutic benefit of combination therapies
CN117321418A (zh) 2021-03-18 2023-12-29 诺华股份有限公司 癌症生物标志物及其使用方法
MX2024005253A (es) * 2021-11-02 2024-05-14 Verastem Inc Metodos para tratar crecimiento celular anormal.
EP4444299A1 (fr) 2021-12-06 2024-10-16 My Personal Therapeutics Ltd Polythérapie contre le cancer
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025073765A1 (fr) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Méthodes de pronostic et de traitement de patients souffrant de mélanome
WO2025080946A2 (fr) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025240847A1 (fr) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025255438A1 (fr) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
KR20020050294A (ko) * 1999-11-22 2002-06-26 피터 기딩스 신규화합물
DE102004018198A1 (de) * 2004-04-15 2005-11-03 Merck Patent Gmbh Sulfonamide
RS50569B (sr) * 2004-06-11 2010-05-07 Japan Tobacco Inc. Derivati 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2h-pirido (2,3-d)pirimidina i slična jedinjenja za lečenje raka
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
WO2008120004A1 (fr) * 2007-04-02 2008-10-09 Astrazeneca Ab Combinaison d'un inhibiteur de mek et d'un inhibiteur de b-raf pour le traitement du cancer
JP5479337B2 (ja) * 2007-07-30 2014-04-23 アルディア バイオサイエンス，インク． Ｍｅｋ阻害剤およびｒａｆキナーゼ阻害剤の組み合わせ、ならびにその使用
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds

Also Published As

Publication number Publication date
CN102655753A (zh) 2012-09-05
ES2986037T3 (es) 2024-11-08
HRP20221304T1 (hr) 2022-12-23
RS59181B1 (sr) 2019-10-31
CA2775803A1 (fr) 2011-04-21
ES2745479T3 (es) 2020-03-02
EP3560498B1 (fr) 2022-08-17
UA105064C2 (uk) 2014-04-10
CO6531498A2 (es) 2012-09-28
DK3560498T3 (da) 2022-11-14
WO2011047238A1 (fr) 2011-04-21
US8952018B2 (en) 2015-02-10
EP2488033A1 (fr) 2012-08-22
PT4159217T (pt) 2024-08-12
EA201290149A1 (ru) 2012-11-30
MX2012004413A (es) 2012-05-08
IL219073A (en) 2016-05-31
EP4397376A2 (fr) 2024-07-10
SI4159217T1 (sl) 2024-09-30
US20140187566A1 (en) 2014-07-03
EP2488033B1 (fr) 2019-06-12
HUE060206T2 (hu) 2023-02-28
RS63702B1 (sr) 2022-11-30
EA020589B1 (ru) 2014-12-30
DK2488033T3 (da) 2019-09-02
ES2930157T3 (es) 2022-12-07
EP4159217A1 (fr) 2023-04-05
ME03497B (fr) 2020-04-20
EP4397376B1 (fr) 2025-11-26
JP5718929B2 (ja) 2015-05-13
CL2012000964A1 (es) 2012-08-31
DOP2012000091A (es) 2013-09-15
CR20120155A (es) 2012-07-05
US20150111904A1 (en) 2015-04-23
BR112012008854B8 (pt) 2021-05-25
AU2010306653B2 (en) 2013-10-24
EP4397376A3 (fr) 2024-10-30
KR101729116B1 (ko) 2017-05-02
BR112012008854A2 (pt) 2015-09-22
AU2010306653A1 (en) 2012-05-10
BR112012008854B1 (pt) 2020-12-29
US8703781B2 (en) 2014-04-22
CN102655753B (zh) 2015-11-25
FI4159217T3 (fi) 2024-08-15
NZ598913A (en) 2013-11-29
JP2013508294A (ja) 2013-03-07
PL3560498T3 (pl) 2022-12-12
PH12012500742A1 (en) 2015-12-11
US20120196879A1 (en) 2012-08-02
EP3560498A1 (fr) 2019-10-30
IL219073A0 (en) 2012-06-28
PT2488033T (pt) 2019-09-10
RS65800B1 (sr) 2024-08-30
PL4159217T3 (pl) 2024-09-30
EP4159217B1 (fr) 2024-05-22
HRP20191617T1 (hr) 2019-12-13
HUE067723T2 (hu) 2024-11-28
EP2488033A4 (fr) 2014-04-30
MY174759A (en) 2020-05-13
PE20121093A1 (es) 2012-09-04
PL2488033T3 (pl) 2019-12-31
HUE046139T2 (hu) 2020-02-28
DK4159217T3 (da) 2024-08-12
LT2488033T (lt) 2019-09-10
KR20120104547A (ko) 2012-09-21
PT3560498T (pt) 2022-11-03
ZA201202612B (en) 2013-09-25
CY1122013T1 (el) 2020-10-14
SI2488033T1 (sl) 2019-10-30
LT3560498T (lt) 2022-11-25
LT4159217T (lt) 2024-08-26
CA2775803C (fr) 2017-11-21

Similar Documents

Publication Publication Date Title
MA33746B1 (fr) Combinaison
MA38643A1 (fr) Combinaisons d'un anticorps anti-pd-l1 et d'un inhibiteur de mek et/ou d'un inhibiteur de braf
HRP20160447T1 (hr) Spojevi benzensulfonamid-tiazola i benzensulfonamid-oksazola
MA52424B1 (fr) Compositions pharmaceutiques comprenant du (2s)--((1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl)-1,4-oxazepane-2-carboxamide
WO2014066606A8 (fr) Combinaison
MA33734B1 (fr) N1-pyrazolospirocétone inhibitrices d'acétyl-coa carboxylase
MA30672B1 (fr) Utilisation de derives de l'azabicyclo hexane
MA30344B1 (fr) Pyrazoles actifs sur la 11-beta-hsd-1
JP2016512825A5 (fr)
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
PH12017502257A1 (en) Compositions and methods of use of phorbol esters
WO2008027584A3 (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
AR052153A1 (es) Composiciones y metodos para la estabilizacion de ingredientes farmaceuticos activos
JP2017519019A5 (fr)
MA35716B1 (fr) Formulations pharmaceutiques
CN114555600A (zh) 作为cdk2/4/6三重抑制剂的氨基嘧啶类化合物
MA53427B1 (fr) Inhibiteurs de l'arginase et leurs méthodes d'utilisation
MA35636B1 (fr) Formulation à libération immédiate de 4-méthyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-méthyl- 1h-imidazol-1-yl)-3-(trifluorométhyl)phényl]benzamide
CA3156457A1 (fr) Composes 1,8-naphtyridin-2-one pour le traitement d'une maladie auto-immune
Rodríguez-Perálvarez et al. Reducing early exposure to calcineurin inhibitors: the key factor for a successful renal sparing strategy
HRP20171295T1 (hr) Derivat 6-okso-1,6-dihidro-piridazina za upotrebu za liječenje hepatocelularnog karcinoma (hcc)
MA39032A1 (fr) Acide 4- [5- (3-chloro-phénoxy) -oxazolo [5,4-d] pyrimidin -2-yl] -2,6-diméthyl-phénoxy}-acétique destiné à être utilisé dans la prévention ou le traitement d'une insuffisance rénale aiguë
CA2798573A1 (fr) Association d'inhibiteurs de la xanthine oxydase et d'antagonistes du recepteur de l'angiotensine ii et son utilisation
MA46358B1 (fr) Compositions pharmaceutiques d'antagoniste de 5-ht6
RU2007116969A (ru) Средство для профилактики или лечения метаболического синдрома